COMP <GO>
RVTY vs MRK // EV/EBITDA & P/E VALUATION
Revvity Inc. (NYSE) VS. Merck & Company Inc. Common Stock (new) (NYSE) • 15-METRIC TALLY: RVTY 2
— MRK 12
▲ EV/EBITDA & P/E VALUATION LEADER: MRK
LAST: $157.00 (-5.30%) • MKT CAP: $18.50B
valuation
48.2x
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
valuation
15.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RVTY VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RVTY | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 74.80% | -33.80 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.10% | 20.70% | -17.60 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 48.2x | 15.3x | +32.90 | MRK | /valuation <GO> |
| Free Cash Flow Yield | 2.75% | 3.42% | -0.67 | MRK | /fcf-yield <GO> |
| Operating Margin | 12.50% | 34.30% | -21.80 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.40% | 28.10% | -19.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 3.70% | 1.30% | +2.40 | RVTY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.18% | 2.26% | -2.08 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.37 | 5.19 | -1.82 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 6.60% | +0.10 | MRK | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.1 | 56.9 | -1.76 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 0.92 | +0.03 | RVTY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 71.3x | 18.4x | +52.90 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $18.50B | $361.02B | -$342.52B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RVTY REV | MRK REV | RVTY GROSS % | MRK GROSS % | RVTY FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.86B | $65.01B | 44.0% | 74.8% | $509.4M | $12.36B |
| FY 2024 | $2.76B | $64.17B | 44.0% | 76.3% | $541.7M | $18.10B |
| FY 2023 | $2.75B | $60.12B | 44.0% | 44.0% | -$32.5M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RVTY // BETA 0.95
MRK // BETA 0.92